NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-510-8998800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."
When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?
NovaBay Pharmaceuticals's stock reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.09. The biopharmaceutical company earned $4.09 million during the quarter, compared to the consensus estimate of $4.69 million. View NovaBay Pharmaceuticals' Earnings History.
When is NovaBay Pharmaceuticals' next earnings date?
What price target have analysts set for NBY?
2 Wall Street analysts have issued 12 month price objectives for NovaBay Pharmaceuticals' shares. Their predictions range from $1.50 to $1.50. On average, they expect NovaBay Pharmaceuticals' stock price to reach $1.50 in the next year. This suggests a possible upside of 138.1% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.
What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.
What are Wall Street analysts saying about NovaBay Pharmaceuticals stock?
Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (3/14/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $31M, which includes a discounted cash flow based asset value for Avenova, using 15% discount rate and 2% terminal growth rate." (3/13/2019)
Has NovaBay Pharmaceuticals been receiving favorable news coverage?
Headlines about NBY stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for NovaBay Pharmaceuticals.
Are investors shorting NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals saw a increase in short interest in July. As of July 31st, there was short interest totalling 725,800 shares, an increase of 104.7% from the June 30th total of 354,500 shares. Based on an average daily trading volume, of 2,840,000 shares, the short-interest ratio is presently 0.3 days. Approximately 14.1% of the shares of the company are short sold. View NovaBay Pharmaceuticals' Current Options Chain.
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include IntelGenx Technologies (IGX), Noxopharm (NOX), Zelda Therapeutics (ZLD), 4d Pharma (DDDD), Verona Pharma (VRP), Tissue Regenix Group (TRX), Rhinomed (RNO), Covalon Technologies (COV), Immunoprecise Antibodies (IPA), Biotron (BIT), Faron Pharmaceuticals Oy (FARN), Novoheart (NVH), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM) and Nuformix (NFX).
What other stocks do shareholders of NovaBay Pharmaceuticals own?
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the folowing people:
- Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
- Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
- Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)
Who are NovaBay Pharmaceuticals' major shareholders?
NovaBay Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.96%) and Jane Street Group LLC (0.18%). Company insiders that own NovaBay Pharmaceuticals stock include Claude Dufresne, Jacques Bonneau, Jean-Sébastien David, Mijia Wu and Pharma (Hong Kong) Co Pioneer. View Institutional Ownership Trends for NovaBay Pharmaceuticals.
Which major investors are buying NovaBay Pharmaceuticals stock?
NBY stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Jane Street Group LLC. Company insiders that have bought NovaBay Pharmaceuticals stock in the last two years include Claude Dufresne, Jacques Bonneau and Jean-Sébastien David. View Insider Buying and Selling for NovaBay Pharmaceuticals.
How do I buy shares of NovaBay Pharmaceuticals?
Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovaBay Pharmaceuticals' stock price today?
One share of NBY stock can currently be purchased for approximately $0.63.
How big of a company is NovaBay Pharmaceuticals?
What is NovaBay Pharmaceuticals' official website?
How can I contact NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.
MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
